Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial

B. Ashleigh Guadagnolo(The University of Texas MD Anderson Cancer Center), Roland L. Bassett(The University of Texas MD Anderson Cancer Center), Devarati Mitra(The University of Texas MD Anderson Cancer Center), Ahsan Farooqi(The University of Texas MD Anderson Cancer Center), Caroline Hempel(The University of Texas MD Anderson Cancer Center), Courtney Dorber(The University of Texas MD Anderson Cancer Center), Tiara Willis(The University of Texas MD Anderson Cancer Center), Wei‐Lien Wang(The University of Texas MD Anderson Cancer Center), Ravin Ratan(The University of Texas MD Anderson Cancer Center), Neeta Somaiah(The University of Texas MD Anderson Cancer Center), Robert S. Benjamin(The University of Texas MD Anderson Cancer Center), Keila E. Torres(The University of Texas MD Anderson Cancer Center), Kelly K. Hunt(The University of Texas MD Anderson Cancer Center), Christopher P. Scally(The University of Texas MD Anderson Cancer Center), Emily Z. Keung(The University of Texas MD Anderson Cancer Center), Robert L. Satcher(The University of Texas MD Anderson Cancer Center), Justin E. Bird(The University of Texas MD Anderson Cancer Center), Patrick P. Lin(The University of Texas MD Anderson Cancer Center), Bryan S. Moon(The University of Texas MD Anderson Cancer Center), Valerae O. Lewis(The University of Texas MD Anderson Cancer Center), Christina L. Roland(The University of Texas MD Anderson Cancer Center), Andrew J. Bishop(The University of Texas MD Anderson Cancer Center)
The Lancet Oncology
November 4, 2022
Cited by 75Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis